Baseline NKT cells as a potential predictive biomarker for treatment with an anchored IL-12 drug conjugate in patients with solid tumors

tolododekin alfa (ANK-101) - Ankyra Therap

https://jitc.bmj.com/content/13/Suppl_2/A208

Kanika Jain 1; Lisa Sturla 2; Jong Chul Park 3; Brendan D Curti 4; Marcus O Butler 5; Gail Iodice 6; Joseph Elassal 7; James L Gulley 8; Jeffrey Schlom 9; Howard Kaufman 10; John M Kirkwood 11; Sailaja Battula 12

Oct 3, 2025